Clinical Trials on Severe Major Depression in Japan

Total 136 results

Astellas Pharma Inc

Completed

Study to Evaluate Safety and Tolerability of FK949E in Elderly Patients With Major Depressive Disorder

Major Depressive Disorder Patients

Japan
Astellas Pharma Inc

Completed

Study to Evaluate Safety and Tolerability of FK949E in Patients With Major Depressive Disorder

Major Depressive Disorder Patients

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Study of Brexpiprazole in Patients With Major Depressive Disorder

Major Depressive Disorder

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 2 Trial of OPC-64005 for Major Depressive Disorder

Major Depressive Disorder

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-Term Study of Brexpiprazole in Patients With Major Depressive Disorder

Major Depressive Disorder

Japan
Showa University

Completed

Analisis of Facors Involved in Antidepressant Treatment Response of Major Depressive Disorder (AFADTRMDD)

Major Depressive Disorder

Japan
Astellas Pharma Inc

Completed

Oral Multiple-dose Study in Patients With Major Depressive Disorder

Major Depressive Disorder

Japan
Astellas Pharma Inc

Completed

Comparison of Plasma Concentration Changes Between Two Types of Tablets of FK949E Administration to Patients With Major Depressive Disorder

Major Depressive Disorder

Japan
Astellas Pharma Inc

Completed

Study to Evaluate the Effect and Safety of Quetiapine Extended Release (XR) (FK949E) in Major Depressive Disorder

Major Depressive Disorder

Japan
GlaxoSmithKline

Completed

Study Of Bupropion SR (323U66) In Patients With Major Depressive Disorder In Japan

Major Depressive Disorder (MDD)

Japan
Nagoya City University

Completed

Brief Multifamily Psychoeducation for Families of Patients With Chronic Major Depression

Major Depressive Disorder

Japan
Eli Lilly and Company

Completed

A Study of LY2216684 in Participants With Major Depression Disorder

Major Depressive Disorder

Japan
Kyoto University
National Center of Neurology and Psychiatry, Japan

Completed

Strategic Use of New Generation Antidepressants for Depression (SUN(^_^)D)

Unipolar Major Depressive Episode

Japan
Eli Lilly and Company

Completed

A Study of Fluoxetine in Major Depressive Disorder (MDD) Short-Term Dosing

Major Depressive Disorder

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder

Major Depressive Disorder

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Long-Term Administration Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder

Major Depressive Disorder

Japan
Eli Lilly and Company

Completed

A Study of Fluoxetine in Major Depressive Disorder (MDD) Long-Term Dosing

Major Depressive Disorder

Japan
Pfizer

Completed

Study Evaluating Long-Term Safety of Desvenlafaxine Succinate Sustained Release With Japanese Adult Subjects in Major Depressive Disorder (MDD)

Major Depressive Disorder

Japan
GlaxoSmithKline

Completed

Controlled-release Paroxetine in Major Depressive Disorder (Double-blind, Placebo-controlled Study)

Depressive Disorder

Korea, Republic of, Japan
Nagoya City University
Kochi University

Completed

Brief Behavioral Therapy for Insomnia (bBT-I) for Depressed Outpatients With Refractory Insomnia

Major Depressive Disorder

Japan
Solvay Pharmaceuticals

Completed

Fluvoxamine Maleate in the Treatment of Depression/Depressive State : A Post-marketing Clinical Study in Children and Adolescents

Major Depressive Disorder

Japan
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD)

Major Depressive Disorder

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder

Major Depressive Disorder

Australia, Taiwan, Malaysia, Korea, Republic of, Japan
Eli Lilly and Company

Completed

A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment

Major Depressive Disorder (MDD)

United States, Puerto Rico, Finland, Japan, Slovakia, Czechia, Croatia
Mochida Pharmaceutical Company, Ltd.
Pfizer

Completed

A Study of MD-120 in Patients With Depression

Major Depressive Disorder

Japan
Takeda

Completed

The Exploratory Study to Investigate the Effect of Ramelteon for Insomnia Patients With Major Depressive Disorder by Using Actigraphy

Insomnia | Major Depressive Disorder

Japan
Takeda

Completed

Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder

Major Depressive Disorder

Japan
Takeda

Completed

Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder

Major Depressive Disorder

Japan
Takeda

Completed

A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder

Major Depressive Disorder

Japan
Eli Lilly and Company

Completed

A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder

Major Depressive Disorder

United States, South Africa, Poland, Ukraine, Japan, Russian Federation, Latvia
Hoffmann-La Roche

Completed

MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy

Major Depressive Disorder

Germany, United States, Taiwan, Mexico, Poland, Russian Federation, Chile, Japan, Romania
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)

Major Depressive Disorder

Japan
Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder

Major Depressive Disorder

United States, Japan
GlaxoSmithKline

Completed

A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)

Depressive Disorder, Major

Korea, Republic of, Japan
Naurex, Inc, an affiliate of Allergan plc

Terminated

Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD)

Depressive Disorder, Major

Slovakia, Poland, Hungary, Japan, Russian Federation
Novartis Pharmaceuticals

Terminated

Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent

Major Depressive Disorder With Suicidal Ideation With Intent

Taiwan, Spain, Germany, Netherlands, Turkey, Mexico, United States, Malaysia, Poland, Canada, Japan, Russian Federation, Argentina, Brazil
AstraZeneca

Terminated

A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.

Major Depressive Disorder

United States, Estonia, Japan, Finland, India
Naurex, Inc, an affiliate of Allergan plc

Terminated

Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)

Depressive Disorder, Major

United States, Poland, Hungary, Japan, Slovakia
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

Depressive Disorder, Major

United States, Bulgaria, Ukraine, Russian Federation, Germany, Finland, Japan, France
Janssen Research & Development, LLC

Terminated

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

Depressive Disorder, Major

United States, Korea, Republic of, Malaysia, Poland, Finland, Chile, Argentina, Slovakia, Ukraine, Denmark
Boehringer Ingelheim

Completed

A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression

Depressive Disorder, Major

Spain, United States, Canada, Germany, Japan, Argentina, Hungary, France, Australia, Bulgaria, Czechia, Poland, Russian Federation, Slovakia
Takeda

Completed

Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder

Depressive Disorder, Major

Taiwan, Germany, Hong Kong, Poland, Malaysia, Romania, Serbia, Ukraine, Japan, Finland, Latvia, Croatia, India, Korea, Republic of, Philippines, Russian Federation
Kibi International University

Completed

Study Protocol for a Smartphone Application-based Intervention for Subthreshold Depression

Subthreshold Depression

Japan
Gunma University

Completed

Treating Depressed Mood With a Smartphone-delivered Positive Word Stimulation for Subthreshold Depression

Subthreshold Depression

Japan
Kibi International University

Completed

Smartphone Intervention for Subthreshold Depression

Subthreshold Depression

Japan
Shionogi
Eli Lilly and Company

Completed

A Study of Duloxetine (LY248686) in Japanese Children and Adolescents With Depressive Disorder

Depressive Disorder

Japan
Shionogi
Eli Lilly and Company

Terminated

A Study of Duloxetine (LY248686) in the Treatment of Japanese Children and Adolescents With Depressive Disorder

Depressive Disorder

Japan
Kyoto University
Nagoya City University

Completed

Telephone Cognitive-Behavioral Therapy (CBT) for Subthreshold Depression and Presenteeism in Workplace

Depression

Japan
University of Jazan
Saudi Board of Community Medicine

Completed

Effects of an Educational Program on Depression Literacy and Stigma Among Secondary School Students in Jazan City

Depression Literacy | Depression Stigma

Saudi Arabia
Chiba University

Completed

An Open Study of Tipepidine Hibenzate in Adolescent Patients With Depression

Adolescent | Depression

Japan

3

Subscribe